Literature DB >> 1247716

Logical approach to lignocaine therapy.

C Aps, J A Bell, B S Jenkins, P A Poole-Wilson, F Reynolds.   

Abstract

Plasma lignocaine concentrations were measured during and after lignocaine infusions administered for suppressing ventricular dysrhythmias. Twenty-four patients with a primary diagnosis of acute myocardial infarction without gross circulatory disturbance received, after a bolus of lignocaine, either 4 mg/min for 30 minutes, 2 mg/min for two hours, then 1 mg/min thereafter or 1 mg/min throughout. The higher dose regimen produced continous therapeutic levels of lignocaine, which were achieved only after four hours by the lower dose. On the other hand, in patients who had undergone cardiac surgery and who had circulatory and heptic dysfunction the lower dose regimen achieved therapeutic levels early. The plasma half life was longer in the surgical group (P less than 0.02). The higher initial infusion rate is recommended for patients with acute myocardial infarction without gross circulatory impairment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1247716      PMCID: PMC1638259          DOI: 10.1136/bmj.1.6000.13

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  16 in total

1.  The physiological disposition of lidocaine and its comparison in some respects with procaine.

Authors:  C Y SUNG; A P TRUANT
Journal:  J Pharmacol Exp Ther       Date:  1954-12       Impact factor: 4.030

2.  Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite.

Authors:  H Halkin; P Meffin; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

3.  Controlled trial of prophylatic treatment with lidocaine in acute myocardial infarction.

Authors:  W Bleifeld; K W Merx; K W Heinrich; S Effert
Journal:  Eur J Clin Pharmacol       Date:  1973-08       Impact factor: 2.953

4.  Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

Authors:  K I Lie; H J Wellens; F J van Capelle; D Durrer
Journal:  N Engl J Med       Date:  1974-12-19       Impact factor: 91.245

5.  The determination of bupivacaine, lignocaine and mepivacaine in human blood.

Authors:  F Reynolds; A H Beckett
Journal:  J Pharm Pharmacol       Date:  1968-09       Impact factor: 3.765

6.  Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias.

Authors:  S Darby; J C Cruickshank; M A Bennett; B L Pentecost
Journal:  Lancet       Date:  1972-04-15       Impact factor: 79.321

7.  Lignocaine given prophylactically to patients with acute myocardial infarction.

Authors:  A Pitt; H Lipp; S T Anderson
Journal:  Lancet       Date:  1971-03-27       Impact factor: 79.321

8.  Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease.

Authors:  R Gianelly; J O von der Groeben; A P Spivack; D C Harrison
Journal:  N Engl J Med       Date:  1967-12-07       Impact factor: 91.245

9.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

10.  The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man.

Authors:  P D Thomson; M Rowland; K L Melmon
Journal:  Am Heart J       Date:  1971-09       Impact factor: 4.749

View more
  14 in total

1.  General derivation of the ideal intravenous drug input required to achieve and maintain a constant plasma drug concentration. Theoretical application to lignocaine therapy.

Authors:  D P Vaughan; G T Tucker
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

2.  Lignocaine: a new technique for intravenous administration.

Authors:  R A Levy; Y Charuzi; W J Mandel
Journal:  Br Heart J       Date:  1977-09

3.  Lignocaine kinetics in cardiac patients and aged subjects.

Authors:  R L Nation; E J Triggs; M Selig
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

4.  Creation of four consecutive instantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with exponentially decreasing delivery rates.

Authors:  J Kraan; L Borgström; G H Koëter; M Laseur; J H Jonkman; O E de Noord
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

6.  Simple lignocaine regimen for transit to hospital after myocardial infarction.

Authors:  J M Barber; D M Boyle; Z Hussain; D G McDevitt
Journal:  Br Heart J       Date:  1977-12

7.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

9.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

10.  Observations on intravenous administration of lignocaine in patients with myocardial infarction.

Authors:  N P Campbell; J G Kelly; A A Adgey; D G McDevitt; J F Pantridge
Journal:  Br Heart J       Date:  1978-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.